Johnson and Johnson (JNJ) Reports Positive Phase 1b Cancer Data

NodeGuardian · 2026-03-18T00:34:19+00:00

Johnson & Johnson reported encouraging Phase 1b results for pasritamig with docetaxel in treating advanced prostate cancer and submitted a Biologics License Application for IMAAVY® to treat autoimmune hemolytic anemia, highlighting its strong clinical pipeline.

NodeGuardian

2026-03-18 00:34:19

Abstract generation in progress

Johnson & Johnson (JNJ) has reported positive Phase 1b data for pasritamig combined with docetaxel in treating metastatic castration-resistant prostate cancer, showing no new safety concerns and durable PSA reductions, strengthening the path for Phase 3 development. Additionally, JNJ submitted a supplemental Biologics License Application for IMAAVY® (nipocalimab-aahu) to the U.S. FDA, aiming to provide the first treatment for warm autoimmune hemolytic anemia. The company, a global pharmaceutical and medical technologies leader, continues to advance its pipeline with promising clinical results.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes